Industry ownership intelligence

Diagnostics & Research insider conviction

Executive and director activity assessed across 28 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboard Healthcare sector Company signals Filing ledger Data API

36/100

Distribution bias

96/100 confidence

Level: Industry
Evidence window: Latest 90 days
Named insiders: 184
Latest evidence: 11 Sep 2026

Capital positioning read

Distribution bias

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Demand a stronger confirmation bar

Evidence in favour

119 distinct acquisition events survive duplicate and security-type controls.
Participation spans 184 named insiders rather than one filing source.
The latest qualifying evidence is fresh, dated 11 Sep 2026.

Decision risks

Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.

Conviction36Distribution bias

Confidence96Deep evidence

Controlled events698directional common-share events

Company breadth28represented companies

Acquisition value$94.2Mnormalized amount

Disposal value$995.1Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15829 Jun

606 Jul

6313 Jul

2020 Jul

6127 Jul

22903 Aug

6710 Aug

12617 Aug

9324 Aug

6231 Aug

1407 Sep

014 Sep

AcquisitionsDisposalsScore 36 · Confidence 96

Relative positioning

Industry peer map

Current score with confidence.

Drug Manufacturers - GeneralBalanced insider tape5594 confidence Pharmaceutical RetailersNo directional read5014 confidence BiotechnologyBalanced insider tape4893 confidence Medical DevicesBalanced insider tape4792 confidence Medical Instruments & SuppliesDistribution bias4192 confidence Diagnostics & ResearchDistribution bias3696 confidence Drug Manufacturers - Specialty & GenericDistribution bias3495 confidence Medical Care FacilitiesConcentrated distribution3287 confidence Healthcare PlansConcentrated distribution3092 confidence Medical DistributionConcentrated distribution3078 confidence Health Information ServicesConcentrated distribution2893 confidence

Directional balance

Controlled event mix

17.0%acquisition

Acquisition events: 119
Disposal events: 579
Net value: -$900.9M

Accumulation

Constructive company clusters

PRPOPrecipio Inc7844 conf.BDSXBiodesix Inc7840 conf.IDXXIDEXX Laboratories Inc7260 conf.DGXQuest Diagnostics Incorporated6991 conf.MTDMettler-Toledo International Inc6676 conf.PSNLPersonalis Inc6662 conf.CRLCharles River Laboratories6288 conf.ADPTAdaptive Biotechnologies Corp5988 conf.

Distribution review

Disposal concentrations

VCYTVeracyte Inc1294 conf.NTRANatera Inc1298 conf.FLGTFulgent Genetics Inc1384 conf.ILMNIllumina Inc1699 conf.SHCSotera Health Co2047 conf.MYGNMyriad Genetics Inc2549 conf.OPKOpko Health Inc2832 conf.NEONeoGenomics Inc2834 conf.

Evidence density

Most active controlled tapes

TMO130 controlled events28Concentrated distribution NTRA95 controlled events12Concentrated distribution ILMN74 controlled events16Concentrated distribution CSTL71 controlled events33Distribution bias ADPT48 controlled events59Accumulation bias TWST45 controlled events28Concentrated distribution GH43 controlled events42Distribution bias CRL29 controlled events62Accumulation bias

Evidence quality

What the filings represent

Common equity786

Equity compensation66

Options and derivatives105

Other securities2

Decision makers

Role participation

Director346

Other executive287

CEO and chair215

Finance leadership54

Other or unspecified54

Large holder3

Quality controls

Evidence usability

Normalized values: 75%
Priced common share: 73%
Named insiders: 184
Controlled events: 698

Auditable evidence